ClinicalTrials.gg
CompletedNCT00717067Updated Nov 19, 2010Results posted

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

A Phase 4 interventional study of Maraviroc and Maraviroc in Human Immunodeficiency Virus (HIV) Infection, sponsored by ViiV Healthcare. Completed at 2 sites in Germany. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-11-19.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to assess whether a dosing adjustment is needed in patients with renal impairment.

02

Conditions studied

  • Human Immunodeficiency Virus (HIV) Infection

Browse trials for

Keywords

  • maraviroc, pharmacokinetics, renal impairment
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 30 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks.
  • (BMI) of approximately 18 to 40 kg/m2 inclusive.
  • Total body weight >50 kg (110 lbs).
  • Male or female subjects between the ages of 18 and 85 years.

Exclusion criteria

Exclusion Criteria:

  • Subjects with acute renal disease and/or history of renal transplant.
  • Supine BP at Screening ≥160 mm Hg systolic or ≥95 mm Hg diastolic.
  • Supine BP at Screening ≤80 mm Hg systolic or ≤40 mm Hg diastolic.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Healthy Subjects

    Subjects with Normal Renal Function (Creatinine Clearance \> 80mL/min) (I) Maraviroc single dose, followed by (II) Maraviroc + Saquinavir/Ritonavir

    Drug: Maraviroc · Drug: Ritonavir · Drug: Saquinavir

  • Experimental
    Mild Renal Impairment

    Subjects with Mild Renal Impairment (Creatinine Clearance \>50 and ≤80 mL/min)

    Drug: Maraviroc · Drug: Ritonavir · Drug: Saquinavir

  • Experimental
    Moderate Renal Impairment

    Subjects with Moderate Renal Impairment (Creatinine Clearance ≥30 and ≤50 mL/min)

    Drug: Maraviroc · Drug: Ritonavir · Drug: Saquinavir

  • Experimental
    Severe Renal Impairment

    Subjects with Severe Renal Impairment (Creatinine Clearance \<30 mL/min)

    Drug: Maraviroc

  • Experimental
    ESRD on Hemodialysis

    Subjects with End Stage Renal Impairment receiving Hemodialysis(Creatinine Clearance \<30 mL/min) (I) Maraviroc single dose one hour following completion of hemodialysis, followed by (II) Maraviroc single dose three hours prior to start of hemodialysis

    Drug: Maraviroc

Interventions

  • Maraviroc 300 mg (150 mg x 2 tablets) x single dose

  • Maraviroc 150 mg tablet twice daily x 7 days

  • Ritonavir 100 mg capsule twice daily x 7 days

  • Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days

  • Maraviroc 150 mg tablet once daily x 7 days

  • Ritonavir 100 mg capsule twice daily x 7 days

  • Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days

  • Maraviroc 150 mg tablet once every 48 hours x 7 days

  • Ritonavir 100 mg capsule twice daily x 7 days

  • Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days

  • Maraviroc 300 mg (150 mg x 2 tablets) x single dose

  • Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis

  • Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Time-curve From Zero to the Last Measured Concentration (AUClast)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) measured in nanograms \* hour divided by milliliters (ng\*hr/mL).

    Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.

  2. AUCtau

    AUCtau: area under the plasma concentration-time profile from time zero to the end of the dosing interval (tau); measured in nanograms \* hours divided by milliliters (ng.hr/mL).

    Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.

  3. Maximum Observed Plasma Concentration (Cmax)

    Maximum observed plasma concentration (Cmax) within the dosing interval; measured in nanograms per milliliter (ng/mL).

    Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.

Secondary outcomes

  1. Plasma Protein Binding

    Percent protein binding (protein unbound maraviroc (MVC) fraction \[percent free\]) was determined by rapid equilibrium dialysis. Percent free = 100 - percent bound.

    Time frame: 2 hours post-dose; normal Day -3 and Day 7; mild moderate: Day 7; severe and ESRD: Day 1

  2. Area Under the Time Curve From 0 to Infinity (AUCinf)

    Area under the plasma concentration-time profile from time zero to the time infinate in subjects who received single dose treatment; measured in nanograms \* hour divided by millilters (ng\*hr/mL).

    Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72

  3. Time of First Occurrence (Tmax)

    Time (hours) of first occurrence (Tmax); time after dosing when Cmax (maximum plasma concentration) occured.

    Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.

  4. Half-life (t1/2)

    Elimination half-life (t1/2) measured in hours: time required for half the quantity of maraviroc to be metabolized or eliminated by normal biological processes.

    Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.

  5. Renal Clearance (CLR) in Subjects With Normal, Mild, Moderate and Severe Renal Function

    Renal clearance (CLR) measured in milliliters per minute (mL/min).

    Time frame: Hour 0 (prior to MVC dosing [single dose] or prior to last MVC dose [multiple dose]) to 72 hours post-dose ; hours 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.

  6. Derivation of Renal Clearance in Subjects With Normal, Mild, Moderate and Severe Renal Function: Ae

    Ae: amount of drug excreted unchanged in the urine; measured in milligrams (mg).

    Time frame: Hour 0 (prior to MVC dosing [single dose] or prior to last MVC dose [multiple dose]) to 72 hours post-dose ; hours 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.

  7. Hemodialysis Clearance of Maraviroc (MVC) in Subjects With End Stage Renal Disease (ESRD) Undergoing Hemodialysis: CLdD

    CLdD: dialysate clearance before dialysis; measured in milliliters per minute.

    Time frame: Before dialysis

  8. Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Maximum Increase and Decrease in Supine Blood Pressure

    Number of subjects with absolute values of supine systolic blood pressure (BP) measured in millimeters of mercury (mm/Hg), range: \<90 mmHg; and supine diastolic blood pressure, range: \<50 mmHg. Number of subjects with a maximum increase and decrease from Baseline in supine systolic BP ≥ 30 mmHg. Number of subjects with a maximum increase and decrease from Baseline in supine diastolic BP ≥ 20 mmHg.

    Time frame: Normal renal function: screening, Day -3 to Day -1; normal, mild and moderate RI: Day 7 to Day 10 and follow-up; severe RI: Day 1 to Day 4 and follow-up; ESRD: Day 1, Day 4, and follow-up

  9. Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Pulse Rate < 40 and > 120 Beats Per Minute

    Number of subjects with pulse rate \< 40 beats per minute (BPM), number of subjects with pulse rate \> 120 BPM.

    Time frame: Normal renal function: screening, Day -3 to Day -1; normal, mild and moderate RI: Day 7 to Day 10 and follow-up; severe RI: Day 1 to Day 4 and follow-up; ESRD: Day 1, Day 4, and follow-up

  10. Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Maximum EGC QTC, QTCB and QTCF Intervals

    Single 12-lead ECG: number of subjects with maximum QTC interval, maximum QTCB interval (Bazett's correction), and maximum QTCF interval (Friderica's correction) measured in milliseconds (msec); range: 450 to \<480 msec, 480 to \<500 msec, and \>500 msec. Maximum QTC interval increase from Baseline; citeria: change = ≥ 30 msec to \< 60 msec, and change = ≥ 60 msec.

    Time frame: Normal renal function: screening, Day -3 and Day -1; normal renal function, mild and moderate RI: Day 7 to Day 9 and follow-up; severe RI: screening, Day 1, Day 3, Day 4, and follow-up; ESRD: screening, Day 1, Day 3, Day 4, and follow-up

07

Results

Posted Dec 21, 2009

Participant flow

Two centers took part in this study between 15 July 2008 and 21 November 2008.

Part 1a: Normal/Mild/Moderate Group
Participant flow — Part 1a: Normal/Mild/Moderate Group
MilestoneHealthy SubjectsMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentESRD: Single Dose
Started66600
Completed66500
Not completed00100
Withdrew: Adverse event00100
Part 1b: Severe Renal Impairment
Participant flow — Part 1b: Severe Renal Impairment
MilestoneHealthy SubjectsMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentESRD: Single Dose
Started00060
Completed00060
Not completed00000
Part 2: End Stage Renal Disease
Participant flow — Part 2: End Stage Renal Disease
MilestoneHealthy SubjectsMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentESRD: Single Dose
Started00006
Completed00006
Not completed00000

Outcome measures

PrimaryArea Under the Plasma Concentration Time-curve From Zero to the Last Measured Concentration (AUClast)

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) measured in nanograms \* hour divided by milliliters (ng\*hr/mL).

Time frame:
Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Time-curve From Zero to the Last Measured Concentration (AUClast)
ng*hr/mLHealthy Subjects: Multiple DoseMild Renal Impairment: Multiple DoseModerate Renal Impairment: Multiple DoseHealthy Subjects: Single DoseSevere Renal Impairment: Single DoseESRD: Single Dose; After DialysisESRD: Single Dose; Before Dialysis
Area Under the Plasma Concentration Time-curve From Zero to the Last Measured Concentration (AUClast)7356.3 ± 2313.459502.1 ± 3599.326496.0 ± 1795.891320.7 ± 988.664255.5 ± 2424.192636.5 ± 1123.342770.1 ± 1356.56
Statistical analysis
  • Healthy Subjects: Multiple Dose vs Mild Renal Impairment: Multiple Dose · ANOVA · Ratio of adjusted geometric means: 129.17 · 90% CI 92.16 to 181.04
  • Healthy Subjects: Multiple Dose vs Moderate Renal Impairment: Multiple Dose · ANOVA · Ratio of adjusted geometric means: 88.31 · 90% CI 61.97 to 125.83
  • Healthy Subjects: Single Dose vs Severe Renal Impairment: Single Dose · ANOVA · Ratio of adjusted geometric means: 322.23 · 90% CI 171.97 to 603.78
PrimaryAUCtau

AUCtau: area under the plasma concentration-time profile from time zero to the end of the dosing interval (tau); measured in nanograms \* hours divided by milliliters (ng.hr/mL).

Time frame:
Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Reported as:
Geometric mean · ng*hr/mL
AUCtau
ng*hr/mLHealthy Subjects: Multiple DoseMild Renal Impairment: Multiple DoseModerate Renal Impairment: Multiple Dose
AUCtau5341.4 ± 1498.278118.7 ± 2995.276193.3 ± 1762.41
Statistical analysis
  • Healthy Subjects: Multiple Dose vs Mild Renal Impairment: Multiple Dose · ANOVA · Ratio of adjusted geometric means: 151.99 · 90% CI 109.53 to 210.92
  • Healthy Subjects: Multiple Dose vs Moderate Renal Impairment: Multiple Dose · ANOVA · Ratio of adjusted geometric means: 115.95 · 90% CI 82.23 to 163.50
PrimaryMaximum Observed Plasma Concentration (Cmax)

Maximum observed plasma concentration (Cmax) within the dosing interval; measured in nanograms per milliliter (ng/mL).

Time frame:
Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLHealthy Subjects: Multiple DoseMild Renal Impairment: Multiple DoseModerate Renal Impairment: Multiple DoseHealthy Subjects: Single DoseSevere Renal Impairment: Single DoseESRD: Single Dose; After DialysisESRD: Single Dose; Before Dialysis
Maximum Observed Plasma Concentration (Cmax)950.91 ± 220.3681150.74 ± 392.167674.20 ± 275.722335.60 ± 393.024801.16 ± 525.656576.7 ± 339.27478.5 ± 198.81
Statistical analysis
  • Healthy Subjects: Multiple Dose vs Mild Renal Impairment: Multiple Dose · ANOVA · Ratio of adjusted geometric means: 121.01 · 90% CI 83.15 to 176.13
  • Healthy Subjects: Multiple Dose vs Moderate Renal Impairment: Multiple Dose · ANOVA · Ratio of adjusted geometric means: 70.90 · 90% CI 47.83 to 105.10
  • Healthy Subjects: Single Dose vs Severe Renal Impairment: Single Dose · ANOVA · Ratio of adjusted geometric means: 238.73 · 90% CI 106.83 to 533.48
SecondaryPlasma Protein Binding

Percent protein binding (protein unbound maraviroc (MVC) fraction \[percent free\]) was determined by rapid equilibrium dialysis. Percent free = 100 - percent bound.

Time frame:
2 hours post-dose; normal Day -3 and Day 7; mild moderate: Day 7; severe and ESRD: Day 1
Reported as:
Number · percent free
Plasma Protein Binding
percent freeHealthy Subjects: Multiple DoseMild Renal Impairment: Multiple DoseModerate Renal Impairment: Multiple DoseHealthy Subjects: Single DoseSevere Renal Impairment: Single DoseESRD
minimum protein unbound MVC fraction19.7 (14.6 to 28.2)15.3 (15.3 to 29.1)18.1 (18.1 to 31.6)14.6 (19.2 to 28.1)19.2 (18.2 to 27.8)18.2 (18.2 to 27.8)
maximum protein unbound MVC fraction26.629.131.628.228.127.8
SecondaryArea Under the Time Curve From 0 to Infinity (AUCinf)

Area under the plasma concentration-time profile from time zero to the time infinate in subjects who received single dose treatment; measured in nanograms \* hour divided by millilters (ng\*hr/mL).

Time frame:
Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72
Reported as:
Geometric mean · ng*hr/mL
Area Under the Time Curve From 0 to Infinity (AUCinf)
ng*hr/mLHealthy Subjects: Single DoseSevere Renal Impairment: Single DoseESRD: Single Dose; After DialysisESRD: Single Dose; Before Dialysis
Area Under the Time Curve From 0 to Infinity (AUCinf)1348.4 ± 986.654367.7 ± 2518.782677.4 ± 1149.852805.5 ± 1374.71
Statistical analysis
  • Healthy Subjects: Single Dose vs Severe Renal Impairment: Single Dose · ANOVA · Ratio of adjusted geometric means: 323.91 · 90% CI 174.32 to 601.88
SecondaryTime of First Occurrence (Tmax)

Time (hours) of first occurrence (Tmax); time after dosing when Cmax (maximum plasma concentration) occured.

Time frame:
Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Reported as:
Median · hours
Time of First Occurrence (Tmax)
hoursHealthy Subjects: Multiple DoseMild Renal Impairment: Multiple DoseModerate Renal Impairment: Multiple DoseHealthy Subjects: Single DoseSevere Renal Impairment: Single DoseESRD: Single Dose; After DialysisESRD: Single Dose; Before Dialysis
Time of First Occurrence (Tmax)1.000 (0.50 to 2.00)1.500 (0.50 to 4.00)2.000 (0.50 to 4.02)2.500 (0.50 to 4.02)2.500 (0.50 to 4.00)3.000 (1.00 to 4.00)2.000 (0.50 to 4.17)
SecondaryHalf-life (t1/2)

Elimination half-life (t1/2) measured in hours: time required for half the quantity of maraviroc to be metabolized or eliminated by normal biological processes.

Time frame:
Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Reported as:
Mean · hour
Half-life (t1/2)
hourHealthy Subjects: Multiple DoseMild Renal Impairment: Multiple DoseModerate Renal Impairment: Multiple DoseHealthy Subjects: Single DoseSevere Renal Impairment: Single DoseESRD: Single Dose; After DialysisESRD: Single Dose; Before Dialysis
Half-life (t1/2)14.22 ± 1.16616.84 ± 5.56816.99 ± 3.14114.36 ± 4.03017.29 ± 4.17115.03 ± 3.32913.86 ± 1.051
SecondaryRenal Clearance (CLR) in Subjects With Normal, Mild, Moderate and Severe Renal Function

Renal clearance (CLR) measured in milliliters per minute (mL/min).

Time frame:
Hour 0 (prior to MVC dosing [single dose] or prior to last MVC dose [multiple dose]) to 72 hours post-dose ; hours 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Reported as:
Geometric mean · mL/min
Renal Clearance (CLR) in Subjects With Normal, Mild, Moderate and Severe Renal Function
mL/minHealthy Subjects: Multiple DoseMild Renal Impairment: Multiple DoseModerate Renal Impairment: Multiple DoseHealthy Subjects: Single DoseSevere Renal Impairment: Single Dose
Renal Clearance (CLR) in Subjects With Normal, Mild, Moderate and Severe Renal Function105.7 ± 56.0077.2 ± 36.7162.5 ± 12.57110.0 ± 38.6726.6 ± 18.84
SecondaryDerivation of Renal Clearance in Subjects With Normal, Mild, Moderate and Severe Renal Function: Ae

Ae: amount of drug excreted unchanged in the urine; measured in milligrams (mg).

Time frame:
Hour 0 (prior to MVC dosing [single dose] or prior to last MVC dose [multiple dose]) to 72 hours post-dose ; hours 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Reported as:
Mean · mg
Derivation of Renal Clearance in Subjects With Normal, Mild, Moderate and Severe Renal Function: Ae
mgHealthy Subjects: Multiple DoseMild Renal Impairment: Multiple DoseModerate Renal Impairment: Multiple DoseHealthy Subjects: Single DoseSevere Renal Impairment: Single Dose
Derivation of Renal Clearance in Subjects With Normal, Mild, Moderate and Severe Renal Function: Ae41.6 ± 22.4539.1 ± 11.2324.9 ± 8.8810.8 ± 7.418.4 ± 6.35
SecondaryHemodialysis Clearance of Maraviroc (MVC) in Subjects With End Stage Renal Disease (ESRD) Undergoing Hemodialysis: CLdD

CLdD: dialysate clearance before dialysis; measured in milliliters per minute.

Time frame:
Before dialysis
Reported as:
Geometric mean · mL/min
Hemodialysis Clearance of Maraviroc (MVC) in Subjects With End Stage Renal Disease (ESRD) Undergoing Hemodialysis: CLdD
mL/minESRD: Single Dose; Before Dialysis
Hemodialysis Clearance of Maraviroc (MVC) in Subjects With End Stage Renal Disease (ESRD) Undergoing Hemodialysis: CLdD36.42 ± 12.710
SecondarySafety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Maximum Increase and Decrease in Supine Blood Pressure

Number of subjects with absolute values of supine systolic blood pressure (BP) measured in millimeters of mercury (mm/Hg), range: \<90 mmHg; and supine diastolic blood pressure, range: \<50 mmHg. Number of subjects with a maximum increase and decrease from Baseline in supine systolic BP ≥ 30 mmHg. Number of subjects with a maximum increase and decrease from Baseline in supine diastolic BP ≥ 20 mmHg.

Time frame:
Normal renal function: screening, Day -3 to Day -1; normal, mild and moderate RI: Day 7 to Day 10 and follow-up; severe RI: Day 1 to Day 4 and follow-up; ESRD: Day 1, Day 4, and follow-up
Reported as:
Number · subjects
Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Maximum Increase and Decrease in Supine Blood Pressure
subjectsHealthy Subjects: Multiple DoseMild Renal Impairment: Multiple DoseModerate Renal Impairment: Multiple DoseHealthy Subjects: Single DoseSevere Renal Impairment: Single DoseESRD: Single Dose; After DialysisESRD: Single Dose; Before Dialysis
BL Supine Systolic Blood Pressure (BP) <90 mmHg0000000
Maximum Increase from BL: Supine Systolic BP≥ 300000000
Maximum Decrease from BL: Supine Systolic BP ≥ 300000010
BL Supine Diastolic Blood Pressure (BP) <50 mmHg0000000
Maximum Increase from BL: Supine Diastolic BP≥ 200010000
Maximun Decrease from BL: Supine Diastolic BP ≥200000000
SecondarySafety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Pulse Rate < 40 and > 120 Beats Per Minute

Number of subjects with pulse rate \< 40 beats per minute (BPM), number of subjects with pulse rate \> 120 BPM.

Time frame:
Normal renal function: screening, Day -3 to Day -1; normal, mild and moderate RI: Day 7 to Day 10 and follow-up; severe RI: Day 1 to Day 4 and follow-up; ESRD: Day 1, Day 4, and follow-up
Reported as:
Number · bpm
Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Pulse Rate < 40 and > 120 Beats Per Minute
bpmHealthy Subjects: Multiple DoseMild Renal Impairment: Multiple DoseModerate Renal Impairment: Multiple DoseHealthy Subjects: Single DoseSevere Renal Impairment: Single DoseESRD: Single Dose; After DialysisESRD: Single Dose; Before Dialysis
Supine Pulse Rate <40 BPM0000000
Supine Pulse Rate >120 BPM0000000
SecondarySafety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Maximum EGC QTC, QTCB and QTCF Intervals

Single 12-lead ECG: number of subjects with maximum QTC interval, maximum QTCB interval (Bazett's correction), and maximum QTCF interval (Friderica's correction) measured in milliseconds (msec); range: 450 to \<480 msec, 480 to \<500 msec, and \>500 msec. Maximum QTC interval increase from Baseline; citeria: change = ≥ 30 msec to \< 60 msec, and change = ≥ 60 msec.

Time frame:
Normal renal function: screening, Day -3 and Day -1; normal renal function, mild and moderate RI: Day 7 to Day 9 and follow-up; severe RI: screening, Day 1, Day 3, Day 4, and follow-up; ESRD: screening, Day 1, Day 3, Day 4, and follow-up
Reported as:
Number · subjects
Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Maximum EGC QTC, QTCB and QTCF Intervals
subjectsHealthy Subjects: Multiple DoseMild Renal Impairment: Multiple DoseModerate Renal Impairment: Multiple DoseHealthy Subjects: Single DoseSevere Renal Impairment: Single DoseESRD: Single Dose; After DialysisESRD: Single Dose; Before Dialysis
Maximum QTC Interval: 450 to < 480 msec1001210
Maximum QTC Interval: 480 to < 500 msec0000000
Maximum QTC Interval: > 500 msec0000000
Maximum QTCB Interval: 450 to < 480 msec1001100
Maximum QTCB Interval: 480 to < 500 msec0000000
Maximum QTCB Interval: > 500 msec0000000
Maximum QTCF Interval: 450 to 480 msec1000100
Maximum QTCF Interval: 480 to < 500 msec0000000
Maximum QTCF Interval: > 500 msec0000000
Max. QTC Interval Increase from BL: change ≥30 <600000001
QTC Interval Increase from BL: change ≥ 600000000

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Subjects—0/6 (0%)2/6 (33.3%)
Mild Renal Impairment—0/6 (0%)6/6 (100%)
Moderate Renal Impairment—0/6 (0%)6/6 (100%)
Healthy Subjects: Single Dose—0/6 (0%)1/6 (16.7%)
Severe Renal Impairment:—0/6 (0%)3/6 (50%)
ESRD: Dosing After Dialysis—0/6 (0%)2/6 (33.3%)
ESRD: Dosing Before Dialysis—0/6 (0%)1/6 (16.7%)
Most frequent other events
Showing 10 of 34
Most frequent other events
EventHealthy SubjectsMild Renal ImpairmentModerate Renal ImpairmentHealthy Subjects: Single DoseSevere Renal Impairment:ESRD: Dosing After DialysisESRD: Dosing Before Dialysis
blood creatinine increasedInvestigations0/64/64/60/60/60/60/6
blood urea increasedInvestigations0/63/60/60/60/60/60/6
headacheNervous system disorders2/63/61/60/60/60/60/6
nocturiaRenal and urinary disorders0/63/63/60/60/60/60/6
flatulenceGastrointestinal disorders2/60/60/61/60/60/60/6
fatigueGeneral disorders0/62/61/60/60/60/60/6
conjunctival hyperaemiaEye disorders0/61/60/60/60/60/60/6
visual impairmentEye disorders0/61/60/60/60/60/60/6
abdominal distensionGastrointestinal disorders0/61/60/60/60/60/60/6
abdominal pain upperGastrointestinal disorders1/60/61/60/60/60/60/6

Baseline characteristics

Age, Customized
Age, Customized(years)Healthy SubjectsMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentESRD on HemodialysisTotal
18 - 44 years001113
45 - 64 years5402415
>= 65 years1253112
Sex: Female, Male
Sex: Female, Male(Participants)Healthy SubjectsMild Renal ImpairmentModerate Renal ImpairmentSevere Renal ImpairmentESRD on HemodialysisTotal
Female222208
Male4444622
08

Study locations

2 sites
  • Pfizer Investigational Site
    Berlin, 10117, Germany
  • Pfizer Investigational Site
    Muenchen, 81241, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2008
First posted
Jul 16, 2008
Start
Jul 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Dec 21, 2009
Last update
Nov 19, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00717067
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
First posted
Jul 16, 2008
Start date
Jul 2008
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Dec 21, 2009
Last update
Nov 19, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion